GentiBio
Tim (Tingxi) Guo is a Senior Scientist at GentiBio since September 2021, with previous roles as Scientist II and Scientist I. Prior to GentiBio, Tim served as a Postdoctoral Associate at the Massachusetts Institute of Technology from October 2019 to August 2021, where a synthetic promoter was developed to enhance the specificity and potency of TCR/CAR-engineered T cell therapies. Tim's earlier experience includes a PhD Candidate/Postdoctoral Researcher position at the University Health Network from September 2013 to August 2019, focusing on the characterization of antigen recognition of non-classical MHC by TCRs and the anti-tumor efficacy of mesothelin-specific CAR T cells. Tim obtained a Doctor of Philosophy in Immunology from the University of Toronto in 2018 and completed an Honours Bachelor of Science in Immunology from the same institution in 2013.
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.